文献速递胸部肿瘤

PET/CT引导下免疫检查点阻断治疗停药策略在转移性肺癌长期应答者中的管理及多模态分析:德国nNGM网络研究

PET/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM).
PubMed 文献 · Ann Oncol · 2025-12-30

该回顾性队列研究纳入455例一线免疫检查点阻断(ICB)治疗≥2年疾病控制的转移性肺癌患者,比较PET/CT引导停药(A组126例)与继续ICB无PET/CT(B组329例)的总生存(OS)。中位随访55个月,A组OS显著更长(中位未达到 vs 82个月,HR 0.35,95%CI 0.18-0.67,P=0.002),尽管治疗时长更短(27 vs 45个月,P<0.001)。A组系统再活检发现第二原发肺癌(SPLC)发生率高(28%),进展事件更多仅用局部消融治疗(53% vs 17%)。

要点

  • PET/CT引导停药组OS显著优于继续治疗组,且治疗时长更短。
  • 长期应答者再活检中第二原发肺癌发生率达28%,需警惕。
  • 停药组进展事件更多仅用局部消融处理,避免全身进展。

核心结论

  • 结构化停药策略对长期ICB应答者可能安全,有助于在广泛进展前早期发现耐药。

研究设计与样本

  • 回顾性队列研究,纳入德国nNGM 21个中心455例一线ICB治疗≥2年疾病控制的转移性肺癌患者。
  • A组为PET/CT引导停药(n=126),B组为继续ICB无PET/CT(n=329),评估总生存(OS)。
  • 对A组持续或进展患者的匹配前后肿瘤样本进行综合基因组分析、组织学肿瘤浸润淋巴细胞定量和空间转录组学分析。

主要发现

  • 中位随访55个月,A组OS显著更长(中位未达到 vs 82个月,HR 0.35,95%CI 0.18-0.67,P=0.002)。
  • A组治疗时长显著更短(27 vs 45个月,P<0.001)。
  • A组系统再活检显示第二原发肺癌(SPLC)发生率为28%。
  • 所有进展事件仅用局部消融治疗的比例:A组53%,B组17%。
  • 治疗后出现的肿瘤具有获得性耐药特征,而SPLC显示原发性耐药特征,包括低PD-L1表达、低肿瘤突变负荷和免疫冷肿瘤微环境。

临床怎么用

  • 对一线ICB治疗≥2年疾病控制的转移性肺癌患者,可考虑PET/CT引导的结构化停药策略。
  • 停药后需系统再活检以鉴别第二原发肺癌与获得性耐药,指导局部或全身治疗。
  • 进展事件可优先考虑局部消融治疗,避免不必要的全身治疗。

局限性

  • 回顾性研究设计,存在选择偏倚可能。
  • 停药组与继续治疗组非随机分组,混杂因素可能影响OS比较。
  • 确证性前瞻性非劣效随机试验正在nNGM进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal duration of immune checkpoint blockade (ICB) in lung cancer remains undefined. Indefinite treatment in long-term responders increases health care burden, exposes patients to avoidable toxicities, and is not supported by any clinical or biological rationale or translational data. Prospective strategies to determine the optimal duration of immunotherapy in lung cancer are urgently needed. PATIENTS AND METHODS: In this retrospective cohort study, 455 patients from 21 National Network Genomic Medicine Lung Cancer Germany (nNGM) centers with ≥2 years of disease control on first-line ICB-based therapy were grouped into PET/CT-guided discontinuation (cohort A, n = 126) or continued ICB without PET/CT (cohort B, n = 329), and assessed for overall survival (OS). Matched pre- and post-ICB tumor samples from cohort A patients with persistent or progressive disease were analyzed by comprehensive genomic profiling, histological tumor-infiltrating lymphocyte quantification, and spatial transcriptomics to explore mechanisms of late resistance. RESULTS: After a median follow-up of 55 months, cohort A showed significantly longer OS [median not reached versus 82 months, hazard ratio 0.35 (95% confidence interval 0.18-0.67), P = 0.002], despite substantially shorter treatment duration (27 versus 45 months, P < 0.001). Discontinuation was either PET-driven (A) or resulted from immune-related toxicity, progression, or patients' choice (B). Systematic re-biopsies in cohort A revealed a high incidence of second primary lung cancers (SPLC, 28%). All progression events were managed exclusively with local (ablative) treatments in 53% (A) versus 17% (B). Tumors that occurred after treatment exhibited features of acquired resistance, whereas SPLC displayed characteristics of primary resistance, including low programmed death ligand 1 expression, low tumor mutational burden, and immunologically cold tumor microenvironments. CONCLUSIONS: A structured discontinuation strategy appears to provide a safe approach for long-term ICB responders, enabling earlier detection of resistance before generalized progression. A confirmatory prospective non-inferiority randomized trial within the nNGM is underway.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Frost N, Joosten M, Franzen J, et al. PET/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM). Ann Oncol. 2025. PMID: 41478526. doi:10.1016/j.annonc.2025.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。